Key result
A single 200 mg oral dose of cibenzoline significantly decreased the left ventricular pressure gradient from 96 to 29 mmHg and improved left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
Why the study?
Does a single oral dose of cibenzoline improve left ventricular diastolic function in patients with hypertrophic cardiomyopathy?
Observational (n=19)
No
Does a single oral dose of cibenzoline improve left ventricular diastolic function in patients with hypertrophic cardiomyopathy?
Absolute Event Rate: 29% vs 96%
p-value: p=<0.0001
A single oral dose of cibenzoline improves left ventricular diastolic function while suppressing systolic function in patients with hypertrophic cardiomyopathy.
Single-dose cibenzoline was associated with improved LV diastolic function in HCM; hypothesis-generating and requires randomized trials before practice change.
The effect of cibenzoline on left ventricular diastolic function was investigated in patients with hypertrophic cardiomyopathy (HCM). Before and 2 h after an oral administration of 200 mg of cibenzoline, echocardiographic, apexcardiographic and gated radionuclide angiographic studies were performed in 12 patients with hypertrophic obstructive cardiomyopathy (HOCM) and 7 with hypertrophic nonobstructive cardiomyopathy (HNCM). After administration of cibenzoline, the left ventricular pressure gradient decreased from 96+/-33 mmHg to 29+/-22 mmHg (<0.0001). Fractional shortening decreased from 53.3+/-7.5 to 45.4+/-6.2% (p=0.0008) in patients with HOCM and from 49.9+/-8.7 to 40.9+/-7.5% (p=0.0039) in patients with HNCM. On the other hand, E-wave velocity increased and A-wave velocity decreased in both groups. The time between the second heart sound and O point was shortened from 253+/-53 to 176+/-21 ms (p<0.0001) in patients with HOCM and from 245+/-54 to 185+/-44 ms (p=0.0050) in patients with HNCM. The time to peak filling rate was shortened from 248+/-79 to 190+/-40 ms (p=0.0072) in patients with HOCM and from 218+/-33 to 163+/-26 ms (p=0.0052) in patients with HNCM. These results indicate that in patients with HCM, cibenzoline suppresses left ventricular systolic function, but can markedly improve left ventricular diastolic dysfunction through its direct action.
No takes yet. Share an insight, caveat, or question.
Hamada et al. (2001) conducted an observational in Hypertrophic cardiomyopathy (n=19). Cibenzoline vs. Baseline was evaluated on Left ventricular pressure gradient (mmHg) in HOCM patients (p=<0.0001). A single 200 mg oral dose of cibenzoline significantly decreased the left ventricular pressure gradient from 96 to 29 mmHg and improved left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: